Zentalis (ZNTL) Pharmaceuticals announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of Gynecologic Oncology, SGO, 2025 Annual Meeting on Women’s Cancer. Azenosertib median duration of response updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer and continues to demonstrate an objective response rate of ~35% in response-evaluable patients. The company is on track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026. The Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug conjugates demonstrating synergistic antitumor effects
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZNTL:
Questions or Comments about the article? Write to editor@tipranks.com